The present invention relates to new salts of omeprazole and esomeprazole respectively, i.e. salts of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole and the (S)-enantiomer thereof. More specifically, the present invention relates to alkylammonium salt of the compounds, formed by a reaction of omeprazole and esomeprazole respectively and an alkylamine with formula NR?1#191R?2#191R?3#191 wherein R?1#191 is a linear, branched or cyclic C?1#191-C?12#191-alkyl group, R?2#191 and R?3#191 are hydrogen. The present invention also relates to a process for preparing crystalline salts, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compound of the invention.
                            本发明涉及
奥美拉唑和
埃索美拉唑的新盐,即5-甲氧基-2-[[(4-甲氧基-3,5-二甲基-2-
吡啶基)-甲基]亚砜基]-1H-
苯并咪唑和其(S)对映体的盐。更具体地说,本发明涉及化合物的烷基
铵盐,由
奥美拉唑和
埃索美拉唑分别与具有公式NR?1#191R?2#191R?3#191的烷基胺反应而成,其中R?1#191是线性,支链或环状的C?1#191-C?12#191烷基,R?2#191和R?3#191是氢。本发明还涉及制备晶体盐的方法,制药制剂以及通过给予本发明化合物治疗胃相关疾病的方法。